Effect of long-acting beta-agonists on the frequency of COPD exacerbations: A meta-analysis

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 204-211

  Wang, J ^a   Nie, B ^a   Xiong, W ^a   Xu, Y ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Long acting beta agonist; Meta analysis

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFECT; DYSPNEA; HUMAN; LUNG FUNCTION; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857996396     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01285.x     Document Type: Article

References (35)

1. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002;57:847-852. (Pubitemid 35178607)
2. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez PR, Salcedo E, Navarro M, Ochando R Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax, 2005;60:925-931. (Pubitemid 41598207)
3. Global initiative for chronic obstructive lung disease (GOLD): report of the GOLD workshop, global strategy for diagnosis, management and prevention of COPD. Updated 2009. http://www.goldcopd.com. (accessed 15 October 2010).
4. Dahl R, Chung KF, Buhl R et al. Efficacy of a new once-daily long-acting inhaled beta2- agonist indacaterol versus twice-daily formoterol in COPD. Thorax, 2010;65:473-479.
5. Donohue JF, Fogarty C, Lötvall J et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine, 2010;182:155-162.
6. Kornmann O, Dahl R, Centanni S et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. European Respiratory Journal, 2011;37:273-279.
7. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R Safety of long-acting β-agonists in stable COPD. Chest, 2008;133:1079-1087. (Pubitemid 351685509)
8. Baker WL, Baker EL, Coleman CI Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed treatment comparison meta-analysis. Pharmacotherapy, 2009;29:891-905.
9. Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Medicine, 2009;7:2.
10. Pauwels R, Calverley P, Buist AS et al. COPD exacerbations: the importance of a standard definition. Respiratory Medicine, 2004;98:99-107. (Pubitemid 38181126)
11. Keene ON, Calverley PMA, Jones PW, Vestbo J, Anderson JA Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal, 2008;32:17-24.
12. Liu D, Menjoge S Statistical analysis of COPD exacerbations (letter). European Respiratory Journal, 2008;32:1422.
13. Rodriguez-Roisin R Toward a consensus definition for COPD exacerbations. Chest, 2000;117:398S-401S.
14. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal, 2002;19:217-224. (Pubitemid 34162820)
15. Cazzola M, MacNee W, Martinez FJ et al. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal, 2008;31:416-469.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. British Medical Journal, 2003;327:557-560. (Pubitemid 37088507)
17. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 1997;315:629-634. (Pubitemid 27387172)
18. Dal Negro RW, Pomari C, Tognella S et al. Salmeterol and fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology & Therapeutics, 2003;16:241-246. (Pubitemid 36794391)
19. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine, 2007;356:775-789. (Pubitemid 46294610)
20. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 2003;58:399-404. (Pubitemid 36560942)
21. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 2003;361:449-456. (Pubitemid 36173708)
22. Chapman KR, Arvidsson P, Chuchalin AG et al. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. Canadian Respiratory Journal, 2002;9:178-185. (Pubitemid 34863635)
23. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest, 2002;122:47-55. (Pubitemid 34754142)
24. Hanania NA, Darken P, Horstman D et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest, 2003;124:834-843. (Pubitemid 37123298)
25. Mahler DA, Wire P, Horstman D et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 2002;166:1084-1091. (Pubitemid 35178706)
26. Stockley RA, Chopra N, Rice L Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax, 2006;61:122-128. (Pubitemid 43235428)
27. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal, 2003;22:912-919. (Pubitemid 37540641)
28. Campbell M, Eliraz A, Johansson G et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine, 2005;99:1511-1520. (Pubitemid 41683932)
29. Rennard SI, Tashkin DP, McElhattan J et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs, 2009;69:549-565.
30. Rossi A, Kristufek P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest, 2002;121:1058-1069. (Pubitemid 34280423)
31. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal, 2003;21:74-81. (Pubitemid 36150304)
32. Tashkin DP, Rennard SI, Martin P et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs, 2008;68:1975-2000.
33. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respiratory Medicine, 2008;102:1511-1520.
34. Hogg JC, Chu F, Utokaparch S et al. The nature of small airway obstruction in chronic obstructive pulmonary disease. New England Journal of Medicine, 2004;350:2645-2653. (Pubitemid 38787999)
35. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest, 2000;18:1557-1565. (Pubitemid 32001777)